UK Opalescence ban is "against single market"
This article was originally published in Clinica
A leading medical device industry lawyer has criticised a recent UK legal ruling giving national courts rather than notified bodies the power to decide whether or not a product is a medical device under the EU Medical Devices Directive (MDD).
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.